Abstract
Hypoxia-inducible factor-1α (HIF-1α) is a transcription factor produced by tumor cells under hypoxic conditions, and a key regulator of a number of genes important in cancer biology. Over-expression of HIF-1α in human tumors is associated with poor prognosis and poor therapeutic outcomes and HIF-1α has been suggested as a novel target for cancer therapy. This article provides a review of PX-478 as the first novel HIF-1α inhibitor in clinical stage for the treatment of solid tumors.
Original language | English |
---|---|
Pages (from-to) | 1583-1585 |
Number of pages | 3 |
Journal | Archives of Pharmacal Research |
Volume | 34 |
Issue number | 10 |
DOIs | |
State | Published - Oct 2011 |